STAT Plus: With hopes running high for Moderna’s coronavirus vaccine, the stock’s value requires an almost mythical leap of faith
Moderna is moving at unprecedented speed to develop a vaccine to prevent infection from the novel coronavirus. But the biotech’s soaring stock price is moving faster, which raises an important question: Are investors taking on too much risk?
Since late February, Moderna shares have more than tripled in value — making it one of the top-performing biotech stocks this year. On Monday, shares hit an all-time high of $66.
